Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial
<strong>Background</strong> Recent efforts in malaria control have resulted in great gains in reducing the burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form dormant liver stages confounds control and elimination efforts. To compare the efficacy...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Published: |
Public Library of Science
2017
|
| _version_ | 1797090007352082432 |
|---|---|
| author | Abreha, T Hwang, J Thriemer, K Tadesse, Y Girma, S Melaku, Z Assef, A Kassa, M Chatfield, M Landman, K Chenet, S Lucchi, N Udhayakumar, V Zhou, Z Shi, Y Kachur, S Jima, D Kebede, A Solomon, H Mekasha, A Alemayehu, B Malone, J Dissanayake, G Teka, H Auburn, S von Seidlein, L Price, R |
| author_facet | Abreha, T Hwang, J Thriemer, K Tadesse, Y Girma, S Melaku, Z Assef, A Kassa, M Chatfield, M Landman, K Chenet, S Lucchi, N Udhayakumar, V Zhou, Z Shi, Y Kachur, S Jima, D Kebede, A Solomon, H Mekasha, A Alemayehu, B Malone, J Dissanayake, G Teka, H Auburn, S von Seidlein, L Price, R |
| author_sort | Abreha, T |
| collection | OXFORD |
| description | <strong>Background</strong> Recent efforts in malaria control have resulted in great gains in reducing the burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form dormant liver stages confounds control and elimination efforts. To compare the efficacy and safety of primaquine regimens for radical cure, we undertook a randomized controlled trial in Ethiopia. <strong>Methods and findings</strong> Patients with normal glucose-6-phosphate dehydrogenase status with symptomatic P. vivax mono-infection were enrolled and randomly assigned to receive either chloroquine (CQ) or artemether-lumefantrine (AL), alone or in combination with 14 d of semi-supervised primaquine (PQ) (3.5 mg/kg total). A total of 398 patients (n = 104 in the CQ arm, n = 100 in the AL arm, n = 102 in the CQ+PQ arm, and n = 92 in the AL+PQ arm) were followed for 1 y, and recurrent episodes were treated with the same treatment allocated at enrolment. The primary endpoints were the risk of P. vivax recurrence at day 28 and at day 42. The risk of recurrent P. vivax infection at day 28 was 4.0% (95% CI 1.5%–10.4%) after CQ treatment and 0% (95% CI 0%–4.0%) after CQ+PQ. The corresponding risks were 12.0% (95% CI 6.8%–20.6%) following AL alone and 2.3% (95% CI 0.6%–9.0%) following AL+PQ. On day 42, the risk was 18.7% (95% CI 12.2%–28.0%) after CQ, 1.2% (95% CI 0.2%–8.0%) after CQ+PQ, 29.9% (95% CI 21.6%–40.5%) after AL, and 5.9% (95% CI 2.4%–13.5%) after AL+PQ (overall p < 0.001). In those not prescribed PQ, the risk of recurrence by day 42 appeared greater following AL treatment than CQ treatment (HR = 1.8 [95% CI 1.0–3.2]; p = 0.059). At the end of follow-up, the incidence rate of P. vivax was 2.2 episodes/person-year for patients treated with CQ compared to 0.4 for patients treated with CQ+PQ (rate ratio: 5.1 [95% CI 2.9–9.1]; p < 0.001) and 2.3 episodes/person-year for AL compared to 0.5 for AL+PQ (rate ratio: 6.4 [95% CI 3.6–11.3]; p < 0.001). There was no difference in the occurrence of adverse events between treatment arms. The main limitations of the study were the early termination of the trial and the omission of haemoglobin measurement after day 42, resulting in an inability to estimate the cumulative risk of anaemia. <strong>Conclusions</strong> Despite evidence of CQ-resistant P. vivax, the risk of recurrence in this study was greater following treatment with AL unless it was combined with a supervised course of PQ. PQ combined with either CQ or AL was well tolerated and reduced recurrence of vivax malaria by 5-fold at 1 y. |
| first_indexed | 2024-03-07T03:12:16Z |
| format | Journal article |
| id | oxford-uuid:b498e80b-ecf5-484a-b330-7672b5dbc724 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T03:12:16Z |
| publishDate | 2017 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:b498e80b-ecf5-484a-b330-7672b5dbc7242022-03-27T04:27:27ZComparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trialJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:b498e80b-ecf5-484a-b330-7672b5dbc724Symplectic Elements at OxfordPublic Library of Science2017Abreha, THwang, JThriemer, KTadesse, YGirma, SMelaku, ZAssef, AKassa, MChatfield, MLandman, KChenet, SLucchi, NUdhayakumar, VZhou, ZShi, YKachur, SJima, DKebede, ASolomon, HMekasha, AAlemayehu, BMalone, JDissanayake, GTeka, HAuburn, Svon Seidlein, LPrice, R<strong>Background</strong> Recent efforts in malaria control have resulted in great gains in reducing the burden of Plasmodium falciparum, but P. vivax has been more refractory. Its ability to form dormant liver stages confounds control and elimination efforts. To compare the efficacy and safety of primaquine regimens for radical cure, we undertook a randomized controlled trial in Ethiopia. <strong>Methods and findings</strong> Patients with normal glucose-6-phosphate dehydrogenase status with symptomatic P. vivax mono-infection were enrolled and randomly assigned to receive either chloroquine (CQ) or artemether-lumefantrine (AL), alone or in combination with 14 d of semi-supervised primaquine (PQ) (3.5 mg/kg total). A total of 398 patients (n = 104 in the CQ arm, n = 100 in the AL arm, n = 102 in the CQ+PQ arm, and n = 92 in the AL+PQ arm) were followed for 1 y, and recurrent episodes were treated with the same treatment allocated at enrolment. The primary endpoints were the risk of P. vivax recurrence at day 28 and at day 42. The risk of recurrent P. vivax infection at day 28 was 4.0% (95% CI 1.5%–10.4%) after CQ treatment and 0% (95% CI 0%–4.0%) after CQ+PQ. The corresponding risks were 12.0% (95% CI 6.8%–20.6%) following AL alone and 2.3% (95% CI 0.6%–9.0%) following AL+PQ. On day 42, the risk was 18.7% (95% CI 12.2%–28.0%) after CQ, 1.2% (95% CI 0.2%–8.0%) after CQ+PQ, 29.9% (95% CI 21.6%–40.5%) after AL, and 5.9% (95% CI 2.4%–13.5%) after AL+PQ (overall p < 0.001). In those not prescribed PQ, the risk of recurrence by day 42 appeared greater following AL treatment than CQ treatment (HR = 1.8 [95% CI 1.0–3.2]; p = 0.059). At the end of follow-up, the incidence rate of P. vivax was 2.2 episodes/person-year for patients treated with CQ compared to 0.4 for patients treated with CQ+PQ (rate ratio: 5.1 [95% CI 2.9–9.1]; p < 0.001) and 2.3 episodes/person-year for AL compared to 0.5 for AL+PQ (rate ratio: 6.4 [95% CI 3.6–11.3]; p < 0.001). There was no difference in the occurrence of adverse events between treatment arms. The main limitations of the study were the early termination of the trial and the omission of haemoglobin measurement after day 42, resulting in an inability to estimate the cumulative risk of anaemia. <strong>Conclusions</strong> Despite evidence of CQ-resistant P. vivax, the risk of recurrence in this study was greater following treatment with AL unless it was combined with a supervised course of PQ. PQ combined with either CQ or AL was well tolerated and reduced recurrence of vivax malaria by 5-fold at 1 y. |
| spellingShingle | Abreha, T Hwang, J Thriemer, K Tadesse, Y Girma, S Melaku, Z Assef, A Kassa, M Chatfield, M Landman, K Chenet, S Lucchi, N Udhayakumar, V Zhou, Z Shi, Y Kachur, S Jima, D Kebede, A Solomon, H Mekasha, A Alemayehu, B Malone, J Dissanayake, G Teka, H Auburn, S von Seidlein, L Price, R Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial |
| title | Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial |
| title_full | Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial |
| title_fullStr | Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial |
| title_full_unstemmed | Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial |
| title_short | Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: A randomized controlled trial |
| title_sort | comparison of artemether lumefantrine and chloroquine with and without primaquine for the treatment of plasmodium vivax infection in ethiopia a randomized controlled trial |
| work_keys_str_mv | AT abrehat comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT hwangj comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT thriemerk comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT tadessey comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT girmas comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT melakuz comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT assefa comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT kassam comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT chatfieldm comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT landmank comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT chenets comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT lucchin comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT udhayakumarv comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT zhouz comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT shiy comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT kachurs comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT jimad comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT kebedea comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT solomonh comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT mekashaa comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT alemayehub comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT malonej comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT dissanayakeg comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT tekah comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT auburns comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT vonseidleinl comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial AT pricer comparisonofartemetherlumefantrineandchloroquinewithandwithoutprimaquineforthetreatmentofplasmodiumvivaxinfectioninethiopiaarandomizedcontrolledtrial |